Ceraxon tablets: composition and action
Ceraxon is sold in several forms:
- injections;
- pills;
- solution for systemic use.
The tablets contain the main active ingredient – citicoline sodium. In addition to this, the composition includes:
- talc;
- castor oil;
- magnesium stearate.
Tablets are packed in 5 pieces in a blister, each box contains 4 blisters. The solution intended for drinking contains the same basic substance - citicoline, and along with it glycerin, sorbidol, sodium citrate, sodium saccharinate, strawberry flavoring. This composition is packaged in unpainted glass bottles with plastic caps. The volume of one bottle is 30 ml. It is convenient to dose using the syringe included in each package.
The drug for administration into a vein is packaged in glass ampoules, with a break line marked. One cardboard package can contain 3 or 5 pieces. Ceraxon mainly acts on brain cells, strengthening membranes, improving the functions of ion exchange pumps of the nervous system, which is due to the production of phospholipids.
In case of severe swelling, the action of the drug relieves pressure at the site of the lesion, which returns the cognitive functions of the brain. In addition, the ability to concentrate is restored and memory improves. If Cerakson is applied promptly at the first symptoms of a stroke, it will be possible to minimize the area of spread of necrotic tissue.
Citicoline is one of the constant elements of the human body, which does not make it possible to evaluate its pharmacokinetics. The substance entering through the gastrointestinal tract is absorbed almost completely. As a rule, 1-2% of the total ingested volume remains unabsorbed. Citicoline is excreted through the kidneys in the urine.
As a result of hepatic metabolism processes, two substances are formed: cytidine and choline. Citicoline is first concentrated in the structures and tissues of the brain. At the same time, fractions of the resulting choline pass into phospholipids, and cytidine derivatives into the composition of nucleic acids.
Ceraxon, 5 pcs., 4 ml, 500 mg/4 ml, solution for intravenous and intramuscular administration
Solution for intravenous, intramuscular administration.
IV, in the form of a slow IV injection (over 3–5 minutes, depending on the prescribed dose) or IV drip infusion (40–60 drops per minute).
The intravenous route of administration is preferable to the intramuscular route. When administered intramuscularly, repeated administration of the drug in the same place should be avoided.
Recommended dosage regimen
Acute period of ischemic stroke and TBI:
1000 mg every 12 hours from the first day after diagnosis, duration of treatment for at least 6 weeks. 3–5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of the drug Ceraxon®.
Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
500–2000 mg per day. The dosage and duration of treatment depend on the severity of the symptoms of the disease. It is possible to use oral forms of the drug Ceraxon®.
Elderly patients
When prescribing Ceraxon® to elderly patients, no dose adjustment is required.
The solution in the ampoule is intended for single use. It must be used immediately after opening the ampoule.
The drug is compatible with all types of intravenous isotonic solutions and dextrose solutions.
Oral solution.
Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup). Take with meals or between meals.
Recommended dosage regimen
Acute period of ischemic stroke and TBI:
1000 mg (10 ml or 1 pack) every 12 hours. Treatment duration is at least 6 weeks.
Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
500–2000 mg per day (5–10 ml or 1 pack (1000 mg) 1–2 times a day). The dosage and duration of treatment depend on the severity of the symptoms of the disease.
Elderly patients
When prescribing Ceraxon® to elderly patients, no dose adjustment is required.
Instructions for using the dosing syringe (Fig. 1):
Picture 1.
1. Place the dosing syringe into the bottle (the syringe plunger is completely lowered) (Fig. 1 (1).
2. Carefully pull the plunger of the dosing syringe until the solution level is equal to the corresponding mark on the syringe (Fig. 1 (2).
3. Before taking, the required amount of solution can be diluted in 1/2 glass of water (120 ml) (Fig. 1 (3).
After each use, it is recommended to rinse the dosing syringe with water.
Recommendations for the use of Ceraxon® in sachets:
1. Separate one bag from another along the tear seam. Holding the bag vertically, carefully tear off its edge along the o (Fig. 2).
Figure 2.
2. The contents of the sachet can be drunk immediately after opening (Fig. 3) or before use can be diluted in 1/2 glass of water (120 ml) (Fig. 4).
Figure 3.
Figure 4.
When is Cerakson prescribed?
Treatment with Ceraxon is indicated in the following cases:
- first 4 hours during primary stroke;
- for rehabilitation after a stroke;
- emergency assistance and to restore the condition impaired as a result of severe head injury;
- cerebrovascular diseases that reduce cognitive function and provoke behavioral changes.
If the patient was administered Ceraxon in the first hours after a traumatic brain injury, the duration of post-traumatic coma will be less than without the help of the drug. In addition, there is a high probability of reducing the severity of neurological abnormalities typical of this type of injury.
If chronic hypoxia has become the reason for the predominance of lack of initiative in a person’s behavior, complete inability in matters of self-care, the drug effectively affects certain areas of the brain, restoring cognitive functions.
Ceraxon (oral solution 100 mg/ml 10 ml No. 10)
A country
Spain
Country of manufacture may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Citicoline
Compound
Package 10 ml
Citicoline sodium 1045 mg.
Excipients: sorbitol - 2000 mg, glycerol - 500 mg, methyl parahydroxybenzoate - 14.5 mg, propyl parahydroxybenzoate - 2.5 mg, sodium citrate dihydrate - 60 mg, sodium saccharinate - 2 mg, strawberry flavor (strawberry essence 1487-S-Lucta) - 4.08 mg , potassium sorbate - 30 mg, citric acid solution 50% - up to pH 5.9-6.1, purified water - up to 10 ml. The solution for oral administration is a clear, colorless liquid with a characteristic strawberry odor.
pharmachologic effect
Nootropic drug. Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis. In the acute period of stroke, citicoline reduces the volume of brain tissue damage and improves cholinergic transmission. In case of traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms; in addition, citicoline helps to reduce the duration of the recovery period. In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive disorders such as memory impairment, lack of initiative, and difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia. Ceraxon® is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.
Indications for use
— acute period of ischemic stroke (as part of complex therapy); — recovery period of ischemic and hemorrhagic strokes; — traumatic brain injury, acute (as part of complex therapy) and recovery period; — cognitive and behavioral disorders in degenerative and vascular diseases of the brain.
Mode of application
The drug is taken with meals or between meals. Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup). Acute period of ischemic stroke and traumatic brain injury: the recommended dose is 1000 mg (10 ml or 1 sachet) every 12 hours. Duration of treatment is at least 6 weeks. Recovery period of ischemic and hemorrhagic strokes, recovery period of traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg/day (5-10 ml 1-2 times/day or 1 sachet ( 1000 mg) 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease. Elderly patients do not require dose adjustment of Ceraxon®. Rules for using a dosing syringe 1. Place the dosing syringe in the bottle (the syringe plunger is completely lowered). 2. Carefully pull the plunger of the dosing syringe until the solution level is equal to the corresponding mark on the syringe. 3. Before taking, the required amount of solution can be diluted in 1/2 glass of water (120 ml). After each use, it is recommended to rinse the dosing syringe with water. Rules for using the drug in sachets 1. Holding the sachet vertically, carefully tear off its edge along the o. 2.The contents of the sachet can be drunk immediately after opening or before use can be diluted in 1/2 glass of water (120 ml).
Interaction
Citicoline enhances the effects of levodopa. Ceraxon® should not be prescribed concomitantly with medications containing meclofenoxate.
Side effect
Very rare (If any of the side effects indicated in the instructions get worse, or any other side effects not listed in the instructions are noticed, you should inform your doctor.
Contraindications
- pronounced vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
- children and adolescents under 18 years of age (due to the lack of sufficient clinical data); - rare hereditary diseases associated with fructose intolerance; - hypersensitivity to the components of the drug. Use during pregnancy and lactation There is not enough clinical data on the use of citicoline during pregnancy. Although experimental studies on animals have not revealed any negative effects, during pregnancy the drug is prescribed only when the expected benefit of therapy for the mother outweighs the potential risk to the fetus. If it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be decided, since there is no data on the excretion of citicoline in breast milk.
special instructions
In the solution for oral administration in the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative. With further storage under recommended conditions, the crystals dissolve within several months. The presence of crystals does not affect the quality of the drug. Impact on the ability to drive vehicles and operate machinery During treatment, patients should be careful when performing potentially dangerous activities that require special attention and speed of psychomotor reactions (including driving a car and other vehicles, working with moving mechanisms, working as a dispatcher and operator).
Dispensing conditions in pharmacies
On prescription
Ceraxon 1000: instructions
Intravenous administration of the drug Ceraxon 1000 should be carried out slowly and evenly, avoiding the creation of a strong stream of flow. When administering drips, the lamb should be in the middle position, which provides up to 60 drops per minute. Jet injection, including into an elastic band, is carried out by applying gentle pressure on the syringe piston. The effectiveness of the drug directly depends on the time of treatment. The sooner the patient was admitted to the care of physicians, and the earlier drug treatment was started, the more positive the result will be.
Ceraxon 1000 is a classic dosage for the treatment of stroke of various etiologies and to minimize the consequences of traumatic brain injuries, which is administered every 12 hours for 6 weeks. After which, if the patient has not lost the swallowing reflex, intravenous administration is replaced by systemic administration through tablets.
If treatment involves taking the solution orally, it must be diluted in 100 ml of drinking water. Drink the medicine with meals. Children may be prescribed the drug in cases of damage to the central nervous system. The dosage for the child is prescribed by the attending physician, depending on his weight, age and condition.
Ceraxon, 10 pcs., 10 ml, 100 mg/ml, oral solution
Solution for intravenous, intramuscular administration.
IV, in the form of a slow IV injection (over 3–5 minutes, depending on the prescribed dose) or IV drip infusion (40–60 drops per minute).
The intravenous route of administration is preferable to the intramuscular route. When administered intramuscularly, repeated administration of the drug in the same place should be avoided.
Recommended dosage regimen
Acute period of ischemic stroke and TBI:
1000 mg every 12 hours from the first day after diagnosis, duration of treatment for at least 6 weeks. 3–5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of the drug Ceraxon®.
Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
500–2000 mg per day. The dosage and duration of treatment depend on the severity of the symptoms of the disease. It is possible to use oral forms of the drug Ceraxon®.
Elderly patients
When prescribing Ceraxon® to elderly patients, no dose adjustment is required.
The solution in the ampoule is intended for single use. It must be used immediately after opening the ampoule.
The drug is compatible with all types of intravenous isotonic solutions and dextrose solutions.
Oral solution.
Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup). Take with meals or between meals.
Recommended dosage regimen
Acute period of ischemic stroke and TBI:
1000 mg (10 ml or 1 pack) every 12 hours. Treatment duration is at least 6 weeks.
Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
500–2000 mg per day (5–10 ml or 1 pack (1000 mg) 1–2 times a day). The dosage and duration of treatment depend on the severity of the symptoms of the disease.
Elderly patients
When prescribing Ceraxon® to elderly patients, no dose adjustment is required.
Instructions for using the dosing syringe (Fig. 1):
Picture 1.
1. Place the dosing syringe into the bottle (the syringe plunger is completely lowered) (Fig. 1 (1).
2. Carefully pull the plunger of the dosing syringe until the solution level is equal to the corresponding mark on the syringe (Fig. 1 (2).
3. Before taking, the required amount of solution can be diluted in 1/2 glass of water (120 ml) (Fig. 1 (3).
After each use, it is recommended to rinse the dosing syringe with water.
Recommendations for the use of Ceraxon® in sachets:
1. Separate one bag from another along the tear seam. Holding the bag vertically, carefully tear off its edge along the o (Fig. 2).
Figure 2.
2. The contents of the sachet can be drunk immediately after opening (Fig. 3) or before use can be diluted in 1/2 glass of water (120 ml) (Fig. 4).
Figure 3.
Figure 4.
Contraindications for use
If, as a result of diagnosing the patient’s condition, the following features are revealed, Cerakson is not prescribed:
- individual intolerance to one of the components of the drug;
- tone of the autonomic nervous system, in its parasympathetic part;
- hereditary fructose intolerance.
Adverse reactions during treatment with Cerakson are extremely rare, among them are:
- coordination problems;
- pain in the occipital region;
- diarrhea;
- appetite disorders;
- insomnia;
- rash.
Sometimes short-term changes in blood pressure are observed, as well as loss of sensation, mainly in the arm and leg on the paralyzed side, if the patient has suffered a stroke.
If any of these reactions occur, you should discuss changing the course of therapy with your doctor.
Buy Ceraxon solution intravenously and intramuscularly 500 mg 4 ml No. 5 in pharmacies
The solution for intravenous and intramuscular administration is a clear, colorless liquid. Indications : acute period of ischemic stroke (as part of complex therapy); — recovery period of ischemic and hemorrhagic strokes; — traumatic brain injury, acute (as part of complex therapy) and recovery period; — cognitive and behavioral disorders in degenerative and vascular diseases of the brain. Dosage regimen IV drug is administered as a slow injection (over 3-5 minutes, depending on the prescribed dose) or drip infusion (40-60 drops/min). The intravenous route of administration is preferable to the intramuscular route. When administered intramuscularly, repeated administration of the drug in the same place should be avoided. Acute period of ischemic stroke and traumatic brain injury: the recommended dose is 1000 mg every 12 hours from the first day after diagnosis; Duration of treatment is at least 6 weeks. 3-5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of the drug Ceraxon®. Recovery period for ischemic and hemorrhagic strokes, recovery period for traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg/day (5-10 ml 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease. Elderly patients do not require dose adjustment of Ceraxon® for intravenous or intramuscular administration. A solution for intravenous and intramuscular administration in an ampoule is intended for single use. After opening the ampoule, the solution should be used immediately. The drug is compatible with all types of intravenous isotonic solutions and dextrose solutions. Side effects Very rare (<1/10,000) (including individual cases): allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, feeling of heat, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath , insomnia, agitation, loss of appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes. In some cases, Ceraxon® can stimulate the parasympathetic system and also cause a short-term change in blood pressure. If any of the side effects indicated in the instructions get worse, or any other side effects not listed in the instructions are noticed, you should inform your doctor. Contraindications for use : severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system); - children and adolescents under 18 years of age (due to the lack of sufficient clinical data); - hypersensitivity to the components of the drug. Use during pregnancy and lactation There is not enough clinical data on the use of citicoline during pregnancy. Although experimental studies on animals have not revealed any negative effects, during pregnancy the drug is prescribed only when the expected benefit of therapy for the mother outweighs the potential risk to the fetus. If it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be decided, since there is no data on the excretion of citicoline in breast milk. Use in children Contraindicated in children and adolescents under 18 years of age. Use in elderly patients Elderly patients do not require dose adjustment of Ceraxon®. Special instructions Impact on the ability to drive vehicles and operate machinery During the treatment period, patients should be careful when performing potentially dangerous activities that require special attention and speed of psychomotor reactions (including driving a car and other vehicles, working with moving mechanisms, work of the dispatcher and operator). Overdose Due to the low toxicity of the drug, cases of overdose have not been described. Drug interactions Citicoline enhances the effects of levodopa. Ceraxon® should not be prescribed concomitantly with medications containing meclofenoxate. Conditions and periods of storage The drug should be stored out of the reach of children at a temperature not exceeding 30°C. Shelf life: 3 years. Conditions for dispensing from pharmacies The drug is dispensed with a prescription.
special instructions
Treatment with Cerakson is often prescribed to premature babies and newborns with brain tissue injuries received during childbirth. The treatment regimen is determined by the attending physician and depends on the Apgar assessment of the child’s condition. Storing the medicine in the refrigerator may cause crystals to form in the solution. It will take at least two months at room temperature to dissolve them. Despite the fact that this does not reduce the quality of the active substance, the drug should still be stored at room temperature not exceeding +30 C.
The empty packaging of the drug must be used within three years from the date of release.
Ceraxon 500 mg 4 ml 5 pcs. solution for intramuscular and intravenous administration
Composition and release form Ceraxon 500 mg 4 ml 5 pcs. solution for intramuscular and intravenous administration
Solution for intravenous and intramuscular administration - 4 ml:
- excipients: 1M hydrochloric acid or 1M sodium hydroxide - up to pH 6.7-7.1; water for injection - up to 4 ml.
Description of the dosage form
Transparent colorless liquid.
Directions for use and doses
The drug is prescribed intravenously or intramuscularly.
The drug is administered intravenously in the form of a slow intravenous injection (over 3-5 minutes, depending on the prescribed dose) or intravenous drip (40-60 drops per minute).
The intravenous route of administration is preferable to the intramuscular route. When administered intramuscularly, repeated administration of the drug in the same place should be avoided.
Recommended dosage regimen
Acute period of ischemic stroke and traumatic brain injury (TBI): 1000 mg every 12 hours from the first day after diagnosis, treatment duration is at least 6 weeks. 3-5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of the drug Ceraxon®.
Recovery period of ischemic and hemorrhagic strokes, recovery period of head injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg per day. Dosage and duration of treatment depending on the severity of the symptoms of the disease. It is possible to use oral forms of the drug Ceraxon®.
Elderly patients
When prescribing Ceraxon® to elderly patients, no dose adjustment is required.
The solution in the ampoule is intended for single use. It must be used immediately after opening the ampoule.
The drug is compatible with all types of intravenous isotonic solutions and dextrose solutions.
Pharmacodynamics
Pharmacokinetics
Since citicoline is a naturally occurring compound found in the body, a classic pharmacokinetic study cannot be performed due to the difficulty in quantifying exogenous and endogenous citicoline. In a pharmacokinetic study on healthy volunteers with oral administration of labeled C14-citicoline, almost complete absorption was observed. Within 5 days after administration of the dose, it was excreted in feces.
Indications for use Ceraxon 500 mg 4 ml 5 pcs. solution for intramuscular and intravenous administration
Ceraxon is a nootropic drug that is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.
Ceraxon is used in the acute and recovery period of ischemic stroke, in the recovery period of hemorrhagic stroke, in the acute and recovery period of traumatic brain injury, in cases of cognitive impairment in degenerative and vascular diseases of the brain.
Contraindications
Cerakson is contraindicated in patients with vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system) and with hypersensitivity to any of the components of the drug. Ceraxon is not used in children under 18 years of age.
Application of Ceraxon 500 mg 4 ml 5 pcs. solution for intramuscular and intravenous administration during pregnancy and lactation
- active ingredients: citicoline sodium - 522.5 mg (equivalent to 500 mg citicoline);
special instructions
Citicoline does not affect the ability to drive vehicles or use machinery.
Overdose
Given the low toxicity of the drug, cases of overdose have not been described even when therapeutic doses are exceeded.
Side effects Ceraxon 500 mg 4 ml 5 pcs. solution for intramuscular and intravenous administration
When using Ceraxon, allergic reactions (rash, itchy skin, anaphylactic shock), insomnia, headache, dizziness, agitation, tremor, numbness in paralyzed limbs, nausea, loss of appetite, changes in the activity of liver enzymes, and fever may occur.
In some cases, Ceraxon can stimulate the parasympathetic system and also have a short-term hypotensive effect.
Drug interactions
Citicoline enhances the effects of L-dihydroxyphenylalanine. Should not be prescribed concomitantly with drugs containing meclofenoxate.
